Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.86 |
| ▸ | LCK | P06239 | 1/20 | 0.86 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.78 |
| ▸ | NPY2R | P49146 | 4/20 | 0.52 |
| ▸ | NPY1R | P25929 | 2/20 | 0.52 |
| ▸ | NPY4R | P50391 | 2/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.52 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.48 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.48 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.48 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.46 |
| ▸ | VEGFA | P15692 | 6/20 | 0.45 |
| ▸ | BECN1 | Q14457 | 3/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.45 |
| ▸ | TCF4 | P15884 | 1/20 | 0.43 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1024602 | 1.00 | EGFR (0.86) | EGFRLCKHKDC1NPY2RNPY1R | |
| SCHEMBL2274 | 1.00 | EGFR (0.86) | EGFRLCKHKDC1NPY2RNPY1R | |
| Zinc Ion SCHEMBL29426351 | 0.95 | HKDC1 (0.86) | EGFRLCKHKDC1NPY2RNPY1R | |
| Bacitracin SCHEMBL29603422 | 0.93 | EGFR (1.00) | EGFRLCKHKDC1NPY2RNPY1R | |
| Bacitracin SCHEMBL20385900 | 0.93 | EGFR (1.00) | EGFRLCKHKDC1NPY2RNPY1R | |
| SCHEMBL4352469 | 0.92 | EGFR (0.77) | EGFRLCKHKDC1NPY2RNPY1R | |
| SCHEMBL1059374 | 0.92 | EGFR (0.73) | EGFRLCKHKDC1NPY2RNPY1R | |
| SCHEMBL21413350 | 0.92 | EGFR (0.73) | EGFRLCKHKDC1NPY2RNPY1R | |
| Chloramphenicol SCHEMBL28142143 | 0.91 | EGFR (0.72) | EGFRLCKHKDC1NPY2RNPY1R | |
| SCHEMBL25547820 | 0.91 | EGFR (0.97) | EGFRLCKHKDC1NPY2RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101370453-B | Compositions and methods for dermal delivery of drugs | NUVO RES INC | 2013-12-18 | — | — | CN | claimed |
| CN-101396335-A | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof | PSIVIDA INC (US) | 2009-04-01 | — | — | CN | claimed |
| CN-101370453-A | Compositions and methods for dermal delivery of drugs | ZARS PHARMA INC (US) | 2009-02-18 | — | — | CN | claimed |
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | UNIV ARIZONA (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4628100-A2 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | Gregg, John Malcolm Hall (US) | 2025-10-08 | — | — | EP | disclosed |
| US-12285413-B2 | Anti-viral agents and methods for administration thereof | GREGG JOHN M H (US) | 2025-04-29 | — | — | US | disclosed |
| US-20250099566-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | NATIONAL INSTITUTES OF HEALTH | 2025-03-27 | — | — | US | disclosed |
| US-20240173456-A1 | THERAPEUTIC COMPOSITIONS FOR WOUND TREATMENT | ARIZONA BOARD OF REGENTS ON BEHALF OF NORTHERN ARIZONA UNIVERSITY | 2024-05-30 | — | — | US | disclosed |
| WO-2023201345-A2 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-10-19 | — | — | WO | disclosed |
| US-20230263778-A1 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | GREGG JOHN M H (US) | 2023-08-24 | — | — | US | disclosed |
| WO-2023137320-A2 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2023-07-20 | — | — | WO | disclosed |
| US-20090280069-A1 | PROGUANIL TO TREAT SKIN/MUCOSAL DISEASES | TOLMAR, INC. (US) | 2009-11-12 | — | — | US | disclosed |
| CN-101513386-A | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof | CONTROL DELIVERY SYS INC (US) | 2009-08-26 | — | — | CN | disclosed |
| CN-101396335-A | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof | PSIVIDA INC (US) | 2009-04-01 | — | — | CN | disclosed |
| CN-101370453-A | Compositions and methods for dermal delivery of drugs | ZARS PHARMA INC (US) | 2009-02-18 | — | — | CN | disclosed |
| CN-101271117-A | Method for measuring content of ayfivin and its preparations by nephelometry | YANXIA GAO (CN) | 2008-09-24 | — | — | CN | disclosed |
| CN-101146516-A | Treatment solution and method for selectively inducing detachment and/or death of lens epithelial cells to prevent posterior capsular opacification | ZHANG JIN JUN (CN) | 2008-03-19 | — | — | CN | disclosed |
| CN-1289067-C | Film forming composition containing sucralose | MCNEIL PPC INC (US) | 2006-12-13 | — | — | CN | disclosed |
| CN-1438873-A | Sustained release drug delivery device and methods of use and manufacture thereof | CONTROL DELIVERY SYS INC (US) | 2003-08-27 | — | — | CN | disclosed |
| CN-1411804-A | Film forming composition containing sucralose | MCNEIL PPC INC (US) | 2003-04-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280069-A1 | PROGUANIL TO TREAT SKIN/MUCOSAL DISEASES | PROKR1, PROKR2, MC1R | EGFR 677/4885LCK 2025/4885HKDC1 3542/4885 |
| US-20230263778-A1 | ANTI-VIRAL COMPOUNDS AND METHODS FOR ADMINISTRATION THEREOF | ACE2, ACE, SARS1 | EGFR 1992/4885LCK 2407/4885HKDC1 1882/4885 |
| US-20260027191-A1 | COMPOSITIONS AND METHODS FOR TREATING BACTERIAL DISEASE | DNMT3L, DNMT3A, DNMT1 | EGFR 3305/4885LCK 3213/4885HKDC1 2983/4885 |
| US-12285413-B2 | Anti-viral agents and methods for administration thereof | ACE2, ACE, MAVS | EGFR 2376/4885LCK 2353/4885HKDC1 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.